Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effects of High Doses of Frusemide on Plasma and Muscle Electrolytes in Patients with Chronic Renal Failure

      , , , , ,

      Nephron

      S. Karger AG

      Frusemide, Chronic renal failure, Muscle electrolytes

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effects of high doses of frusemide on plasma and muscle electrolyte composition were investigated in 20 patients with chronic renal failure (CRF), in 5 of them complicated by superimposed cardiac decompensation (CRF + CD). In patients with uncomplicated CRF, short-term frusemide therapy resulted in a decrease of muscle water content, while no significant effect on muscle electrolyte and protein nitrogen contents was observed. On the contrary, in patients with CRF + CD, muscle water (both in the extracellular and intracellular phases), sodium and chloride concentrations fell significantly as a result of frusemide therapy. Muscle potassium remained unchanged, even if related to the cell protein content, in both groups of patients. These results support the conclusion that, in patients with uncomplicated CRF, short-term frusemide therapy acts primarily on plasma and extracellular volume with little or no modification of intracellular fluids and tissue electrolyte composition.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1974
          1974
          28 November 2008
          : 13
          : 3
          : 235-244
          Affiliations
          Institute of Medical Pathology (Head: Prof. E. Fiaschi), University of Padua, Padua
          Article
          180398 Nephron 1974;13:235–244
          10.1159/000180398
          4418699
          © 1974 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10
          Categories
          Paper

          Cardiovascular Medicine, Nephrology

          Chronic renal failure, Frusemide, Muscle electrolytes

          Comments

          Comment on this article